In furtherance to letter dated 21st March, 2020 intimating USFDA exemption from import alert for APls Chloroquine Phosphate and Hydroxycholoroquine Sulfate manufactured from Company's APls manufacturing facility situated at Ratlam (M.P), Ipca Laboratories has now informed that the USFDA vide its email dated 23rd June 2020 has communicated to the Company that shortage implications for Chloroquine Phosphate API has changed and Chloroquine Phosphate drug product is no longer in shortage and therefore, no shipment of API Chloroquine Phosphate will be excluded from the import alert. USFDA has also informed hat due to potential shortage implications and/ or medical necessity, exception to the import alert has been made for API Hydroxychloroquine Sulfate. USFDA has further informed that this exception will be re-considered if the shortage implications change.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1850.40 |
| Dr. Reddys Lab | 1310.50 |
| Cipla | 1365.25 |
| Zydus Lifesciences | 939.10 |
| Lupin | 2442.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: